44
Participants
Start Date
April 1, 2022
Primary Completion Date
October 1, 2024
Study Completion Date
December 1, 2025
sintilimab
Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
Trastuzumab
Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
S-1 plus oxaliplatin
"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) \< 1.25 m2, 50 mg for BSA 1.25 to \<1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area \<1.25m2: Tegio 40mg bid day 1 \~ 14; Body surface area 1.25 \~ \<1.5m2: Tegio 50mg bid day 1 \~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 \~ 14; 3 cycles before surgery and 3 cycles after surgery."
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing
Aiping Zhou
UNKNOWN